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Background: The discovery of cytosine hydroxymethylation (5hmC) as a mechanism that potentially controls DNA
methylation changes typical of neoplasia prompted us to investigate its behaviour in colon cancer. 5hmC is
globally reduced in proliferating cells such as colon tumours and the gut crypt progenitors, from which tumours
can arise.
Results: Here, we show that colorectal tumours and cancer cells express Ten-Eleven-Translocation (TET) transcripts
at levels similar to normal tissues. Genome-wide analyses show that promoters marked by 5hmC in normal tissue,
and those identified as TET2 targets in colorectal cancer cells, are resistant to methylation gain in cancer. In vitro
studies of TET2 in cancer cells confirm that these promoters are resistant to methylation gain independently of
sustained TET2 expression. We also find that a considerable number of the methylation gain-resistant promoters
marked by 5hmC in normal colon overlap with those that are marked with poised bivalent histone modifications in
embryonic stem cells.
Conclusions: Together our results indicate that promoters that acquire 5hmC upon normal colon differentiation
are innately resistant to neoplastic hypermethylation by mechanisms that do not require high levels of 5hmC in
tumours. Our study highlights the potential of cytosine modifications as biomarkers of cancerous cell proliferation.Background
Cancer is a complex disease characterised by genetic
and epigenetic aberrations. DNA methylation, an epigen-
etic mark catalysed by de novo DNA methyltransferases
(DNMT) [1], can modulate gene activity and its distribu-
tion across the genome is grossly disrupted in neoplasia
[2]. The gain of methylation that frequently associates
with the silencing of tumour suppressor genes can occur
through the targeting of methylating complexes [3-5]
but may also result from a failure to protect an
unmethylated state [6]. Global losses, prominent across
large expanses of the genome and thought to modulate
genome function through higher order chromatin ar-
chitectures [7-9], may occur through passive DNA* Correspondence: amm95@bath.ac.uk
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unless otherwise stated.demethylation caused by a failure to maintain DNA
methylation during DNA replication [10]. The precise
nature of the processes that govern DNA methylation
changes in cancer are nevertheless still poorly defined
and the recent discovery of active DNA demethylation
mechanisms [11-16] bring about an additional level of com-
plexity to our understanding of how such changes occur.
Methylation in DNA can be actively removed through
oxidative demethylation by the TET family of alpha-
glutarate-dependent oxygenases (TET1, TET2 and
TET3) [15,17]. Further oxidation of 5hmC generates
5-formylcytosine (5fC) and 5-carboxylcytosine (5caC)
[18] that are readily recognised by DNA repair processes
[19]. The interconversion of cytosine modifications is now
understood to be involved in the control of epigenetic
plasticity and gene expression programmes [20].
Global reduction in 5hmC has been observed in all
cancers studied to date [21-27], including colon cancer
[21,28,29]. However, many but not all neoplasias show
changes in expression levels of TETs [24-26,30-35].ntral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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frequently associate with mutations in TET2 [30,36,37]
but changes in 5hmC levels are also thought to result
from inhibition of TET activity by the onco-metabolite
2-hydroxyglutarate which accumulates through mutations
of isocitrate dehydrogenases (IDH1/2) [38,39]. Impor-
tantly, reduced 5hmC does not always correlate with pre-
sence of IDH mutation [22,34] and IDH mutations are
largely mutually exclusive to TET2 mutations in leukae-
mia [38]. In colon cancer on the other hand, mutations in
TETs and IDHs are very rare [31,40]. Thus reduction of
5hmC appears to be a universal feature of tumourigenesis
but factors implicated in regulating cytosine hydroxylation
show tumour-type-specific aberrations.
The aim of this study was to provide an insight into
the potential role of oxidative demethylation in the pro-
gressive changes in DNA methylation that occur in
colon tumourigenesis. Molecular characterisation of the
behaviour of 5hmC, 5mC and TETs in colon cancer tis-
sues and cancer cells shows that changes in 5hmC levels
in proliferating cells do not correlate with TET tran-
scripts levels or with identifiable mutations in their cata-
lytic domains. Importantly, we show that presence of
5hmC at promoters in normal tissues associates with re-
sistance to methylation gain in colon cancer.
Results and discussion
Two distinct classes of 5hmC enrichment profiles are
observed at active genes in normal human colon
We first set out to identify genes marked by 5hmC in
colon by hmeDIP-seq in order to ultimately follow their
methylation fate in cancer. Initial hmeDIP-seq on five
DNA samples from normal mucosa of affected patients
showed 5hmC enrichment at promoters, absent at the
transcription start site (TSS), abundant within the body
of genes and underrepresented within intergenic regions
(Figure 1a and b).
From the profiling of 5hmC content across genes we
identified two types of enrichments at gene promoters
(Figure 1c). A ‘narrow’ type was observed after ranking
5hmC read content inside a window of -1 kb to +0.5 kb
of the TSS and a ‘broad’ type after ranking by 5hmC read
content in the gene body (from TSS to the TTS). We
identified 2,156 unique ‘narrow’ and 2,199 unique ‘broad’
promoters (listed in Additional file 1).
The ‘narrow’ and ‘broad’ profiles were distinct in terms
of promoter CpG content (Figure 1d) and in distribution
of 5hmC around promoter CpG islands (Figure 1e). Pro-
moters with the ‘narrow’ profile were enriched for inter-
mediate CpG content promoters (ICP) whereas the
‘broad’ promoters where mostly high in CpG content
(Figure 1d). Both promoter types showed that 5hmC is
enriched within the shores of promoter CpG islands,
more so within the upstream shore, and a higher overallcontent of 5hmC for the ‘narrow’ type (Figure 1e). Note,
however, that the enrichment of 5hmC in the down-
stream shore of ACTN2 is lower than that for AGAP1.
The levels measured over the islands represent an aver-
age of the population for each type of promoter, and
thus individual loci may not necessarily display the full
enrichment profile across the associated promoter CpG
island. Additional file 2 shows further examples to illus-
trate this. Interestingly, comparison of the 5hmC profiles
with Illumina expression array data from four normal
cases showed that ‘narrow’ promoter genes are less ac-
tive than the ‘broad’ type (Figure 1f ), in accordance with
previous correlations made for higher 5hmC content at
promoters and reduced gene activity in mouse and hu-
man ES cells [41,42]. Biological processes also typified
the 5hmC promoters; gene ontology categories indicative
of gut function were enriched for the ‘narrow’ type
whereas cell differentiation and development where en-
riched for the ‘broad’ type (Additional file 2).
Together these data show that the content and dis-
tribution of 5hmC within promoters and gene bodies
correlates with gene activities involved in normal gut
epithelial function and differentiation.
5hmC enrichment is similar to 5mC enrichment at genic
regions
Next we examined DNA methylation content with re-
spect to the 5hmC profiles by comparing our hmeDIP-
seq data to published meDIP-seq data for normal colon
tissue [43] (Additional file 3). We generated heatmaps
for 5hmC and 5mC enrichment profiles from -3 kb
to +20 kb around the TSS (Additional file 3a). Ten clusters
were generated based on the distribution of 5hmC and
5mC within this window. Overall we found that where
5hmC-specific enrichment is observed, the enrichment
profiles are similar for 5mC (Additional file 3a). The ex-
ception was cluster 2 where there was more DNA me-
thylation near the TSS than 5 hmC. Further comparison
of 5hmC and 5mC profiles closer to the TSS (-3 kb
to +3 kb) of all loci suggest that the differences in enrich-
ment patterns for 5hmC and 5mC occur near the TSS and
upstream promoter region (Additional file 3b). This sug-
gests that several gene promoters may have DNA methy-
lation without 5 hmC.
The heatmaps also identified the ‘narrow’ promoters as
typified by clusters 3 and 8 whereas the ‘broad’ promoters
fell within clusters 5, 6, 7 and 9 (Additional file 3c). With
the exception of clusters 2 and 3 that showed an enrich-
ment for LCP promoters, most of the 5hmC/5mC clusters
fell with promoters of an intermediate or high CpG con-
tent (Additional file 3e).
We then compared the meDIP-seq methylation clusters
to the methylation levels assessed by the Infinium27k
arrays in 17 normal samples from our patient cohort
Figure 1 5hmC promoter profiles and their association with active genes in normal colon. (a) hmeDIP-seq profile for all genes around the
TSS in normal colon tissue (n = 5). (b) Quantification of 5hmC enrichments in genomic features. (c) Two distinct promoter profiles were identified.
Left panel: high 5hmC within a promoter window (-1 kb to +0.5 kb) with a ‘narrow’ promoter profile. Right panel: high 5hmC within gene bodies
(from the TSS to the TTS) with a ‘broad’ promoter profile. Below are examples of each type of profile. (d) 5hmC and CpG content in the promoter.
High, intermediate and low CpG content (HCP, ICP and LCP, respectively). Inset numbers represent the number of promoters for each category
(LCP numbers not shown). (e) 5hmC content at promoter CpG islands. The levels represent an average of the population for each promoter type,
thus individual loci may not necessarily display the full profile. Additional file 2 shows further examples. (f) Expression levels (log2 microarray
intensity) of genes associated with 5hmC promoter profiles (P values were obtained by a Wilcox test).
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the maximal distance of the Infinium probes to the TSS is
1499 bp. The highest methylation levels for these probes
were around the promoters grouped within clusters 1
and 2, which correspond to the meDIP-seq data where the
highest methylation enrichment was observed (Additional
file 3a and e). Similarly clusters 4 to 9 which all reportedlow amounts of DNA methylation around the TSS by
meDIP-seq also had lower levels of DNA methylation at
the corresponding Infinium probes (Additional file 3a
and e).
Thus in our normal colon tissues, the Infinium arrays
concur with meDIP-seq enrichment patterns proximal
to the TSS of genes.
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correlate with changes in TET transcript levels
Having established profiles for 5hmC and 5mC in nor-
mal colon we next analysed their behaviour in neoplasia.
Our colon cancer cohort is composed of 47 normal tis-
sues, 36 adenomas and 31 adenocarcinomas (Additional
file 1). We confirmed that 5hmC and 5mC are globally
reduced during colon cancer progression using liquid
chromatography mass spectrometry (LCMS) and im-
munofluorescence (IF) (Figure 2a and b). The IF also
shows that 5hmC is concentrated in the differentiated
colon epithelium and is low in the base of the crypts
and tumours consistent with previous reports [21]. Im-
portantly, we observed TET1, TET2 and TET3 were con-
sistently transcribed in normal and tumour tissue and
that the absolute levels of TET1 were low relative to
TET2 and TET3 by Sybr-Green qRT-PCR (Figure 2c).
Further analysis of TET expression in normal-tumour
matched cases by Taqman qRT-PCR showed no cor-
relation with the changes in global levels of 5hmC
(Additional file 4). Moreover, mining of recently pub-
lished data sets [31,44] indicates that TETs are present in
normal crypt and differentiated epithelium and tumours.
Mutation at the Fe2 and a-KG binding pockets could
account for a lack of TET activity [30] but these were
specifically excluded in our sample set through targeted
exonic sequencing (Additional file 5a and Additional
methods). We identified non-synonymous mutations
elsewhere in the catalytic domains of TETs but their
presence did not correlate with the changes in global
5hmC levels (Additional file 5b). Reduction of 5hmC in
tumours may also be due to inhibition of TETs by me-
tabolites that accumulate through mutation of IDH1/2,
Fumarate hydratase (FH) or Succinate dehydrogenase
(SDH) [39,45]. In our study IDH1/2 mutations were ex-
cluded in a subset of samples (not shown) and recent
larger studies have shown IDH1/2, FH or SDH mutation
is rare or absent in colon cancer [31,40].
We do not have TET protein data associated with
our sample set and therefore we cannot exclude that
the global reduction in 5hmC could be due to post-
transcriptional events with an impact on variations in the
stability or activity of TETs. However, the detection of
mRNA at levels similar to the normal tissues suggests that
the reduced levels of 5hmC that we uncover in all our
colon tumours is unlikely to be due to an absence or mu-
tation of TETs or an inhibition by currently recognised
onco-metabolites.
5hmC is reduced across the genome of tumours with a
small effect on gene transcription
We profiled 5hmC in four matching adenocarcinomas.
The hmeDIP-seq read content in tumours showed an
overall similar distribution to the normal tissue but withmarkedly reduced 5hmC levels across the genome as
assessed by 5hmC content within repetitive elements
(Additional file 6) and within genes (Additional file 7a
and b). The reduced level of 5hmC in tumours com-
pared to normal was confirmed at selected loci by a
glycosylase-restriction enzyme sensitive assay (gluc-MS-
qPCR - Additional file 7c) indicating that genes continue
to be marked by a reduced amount of 5hmC in tumours.
Illumina expression array data generated from four
normals and 14 tumours showed a small but statistically
significant reduction in gene activity for genes with
‘broad’ 5hmC promoters (Additional file 7d). Thus, al-
though 5hmC associates with active gene transcription,
the reduction of 5hmC in tumours were accompanied by
very small expression level changes. These results indi-
cate that genes that acquire 5hmC in normal colon are
transcriptionally active in tumours and suggest that low
levels of 5hmC do not hinder transcription.
Loci marked by 5hmC in normal have an innate
resistance to DNA hypermethylation in cancer
To ascertain whether promoters normally marked by
5hmC undergo DNA methylation changes in colon can-
cer, we assessed DNA methylation in 17 tumours matched
to the normal tissues using Infinium methylation arrays.
The Infinium27k arrays are a robust platform for quan-
titative measurement of the DNA methylation status of
27,578 CpG sites located at the promoter regions of
14,495 protein-coding genes [43,46]. Infinium technology
is based on bisulfite conversion that does not distinguish
between 5mC and 5hmC. However, 5hmC only makes up
a small percentage of modified cytosines in normal colon
and an even smaller percentage in colon cancer tissue.
Based on the median levels of 5hmC detected by LCMS
(Figure 2), only about 2.4% of 5mC reported in the Infi-
nium data is likely to be undistinguishable from 5hmC in
normal cells, and about 0.7% in tumours.
Methylation changes in our patient cohort showed both
gain and loss of promoter DNA methylation (Figure 3a).
To refine our analysis of 5hmC content to changes in
DNA methylation at the promoters assessed by the Infi-
nium platform, we counted the hmeDIP-seq reads from
normals in 200 bp windows around the Infinium probes
(Figure 3b). After ranking by read content we identified
the top 3,000 5hmC enriched loci (5hmC-high) as well as
3,000 loci where 5hmC was low or undetected (5hmC-
low). Interestingly, by this measurement of read counts
around the Infinium probes, we observed that promoters
with high 5hmC in normal are either resistant to methyla-
tion change or are prone to methylation loss (79% loss vs.
21% gain from 676 probes with significant change out of
3,000) and that 5hmC marked promoters more frequently
associate with a range of intermediate levels of methyla-
tion in normal (Figure 3c left panel and d). 5hmC low
Figure 2 (See legend on next page.)
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Figure 2 Reduced 5hmC in tumours without global changes in TETs transcripts. (a) Global content of 5hmC and 5mC in normal (N), adenoma
(Ad) and adenocarcinoma (T) DNA by mass spectrometry (P values were obtained by a Wilcox test). (b) Representative images from a colon cancer
tissue microarray immunofluorescence. Arrows indicate the epithelium, arrowheads the stroma. (c) Absolute levels of TETs (standard curve method) in
selected cases from our colon cancer cohort. Orange vertical bands represent the median. Negative values indicate TETs transcripts are less abundant
than B2M transcripts. There was no significant change in levels across tissues but considerable variation within tissues.
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methylation in normal and showed an increased propen-
sity to methylation gain, albeit methylation loss was also
observed (56% gain vs. 44% loss from 379 probes with sig-
nificant change out of 3,000) (Figure 3c right panel and d).
We also find that the methylation-prone genes that lack
5hmC in normal have a low level of expression in the nor-
mal tissue (Figure 3d, right panel), in agreement with a
recent report where propensity to methylation gain in tu-
mours is frequent at promoters of genes with low expres-
sion in the normal tissue [47].
Importantly, the reciprocal pattern of high/low 5hmC in
normal with loss/gain of methylation in adenocarcinoma
was already present at the adenoma stages (Additional
file 8a and b) and observed at CpG islands and island
shores (Additional file 8c). This reciprocal pattern wasFigure 3 Promoters marked by 5hmC in normal colon resist DNA methyl
(n = 17) relative to matched normal tissues (n = 17) (Infinium arrays). Each dot
content measured in windows around the Infinium probes (black bars). CpG i
promoters on the methylation states. (d) Left panel: 5hmC content around th
High 5hmC promoters are prone to loss of DNA methylation in tumours whe
(limma geneSetTest). Middle panel: 5hmC content in normal and levels of DN
across a range of methylation levels in normal (P values from a Wilcox test). R
DNA methylation prone genes (5hmC low) have low expression in the norma
5mC levels in normal to the 5mC changes in tumours at selected loci.also present at previously identified colon cancer-specific
small regions of differential DNA methylation (sDMRs)
[8] (Additional file 8d) and clearly observed and verified in
a number of colon cancer relevant gene promoters
(Figure 3e and Additional file 9).
Together these results indicate that gene promoters
marked with 5hmC in normal rarely become hypermethy-
lated when 5hmC is reduced in tumours. Indeed these
promoters have a tendency to lose DNA methylation in
cancer. We also identified 117 promoters where 5hmC
was still detected in adenocarcinomas, albeit at very low
levels, and found that these where three times more likely
to have lost methylation rather than gain (27% vs. 8.5%,
respectively) (Additional file 10). These results may sug-
gest that DNA demethylation at a subset of proximal pro-
moters could be mediated via hydroxymethylation and/oration gain in tumours. (a) DNA methylation changes in adenocarcinoma
represents a CpG (grey dots are changes with P <0.01). (b) 5hmC read
sland (CpGi) as orange bar. (c) Overlay of 5hmC high or 5hmC low
e Infinium probes of promoters with a significant change in methylation.
reas low 5hmC promoters are prone to methylation gain in tumours
A methylation in normal to show that methylation gain or loss occurs
ight panel: 5hmC content in normal and expression levels in normal.
l tissue (P values from a Wilcox test). (e) Heatmap comparing 5hmC and
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ing complexes as previously suggested [48,49].
There is strong evidence from cell labelling experiments
that colon cancer can originate from the stem cell/pro-
genitor compartment [50]. Our data, and that of others
[21], showing that global 5hmC levels are low in the stem
cell compartment and in cancer tissues may suggest that
5hmC is not lost in colon cancer. Rather, 5hmC may not
accumulate due to an aberrant progenitor-like proli-
ferative state. One explanation for why the loci that would
accumulate 5hmC upon terminal differentiation are see-
mingly more resistant to gain of DNA methylation in can-
cer, in contrast with loci that do not accumulate 5hmC,
could be that the TETs in cancer cells are bound to their
target promoters to prevent de novo DNA methylation.
TET2 marks promoters in cancer cells that resist DNA
methylation gain in primary tumours but is not required
to maintain a demethylated state
In order to examine whether TETs are bound to DNA in
cancer cells we turned to the colorectal cancer cell line
HCT116. This cell line shows low global levels of 5hmC
and TET2 and TET3 transcript levels comparable to that
observed in normal and adenocarcinoma tissue (Additional
file 11a to c). Despite the extremely low global content of
5hmC in these cells, lower than that seen in the primary
tissues, TET2 and TET3 proteins can be detected in the
nuclear fraction (Additional file 11d) albeit a sizeable
amount of TET2 is present in the cytoplasm (Additional
file 11d and e). A similar subcellular distribution of TET2
is observed in normal colon crypts and tumours by immu-
nohistochemistry (Additional file 12).
Chromatin immunoprecipitation sequencing (ChIP-seq)
revealed that TET2 preferentially binds to gene promoters
within 1 kb of the TSS (Figure 4a and b). Overall 3,144
promoters were identified as TET2 targets (Additional
file 1) of which the large majority were CpG island-
containing promoters of the HCP type (Figure 4c and d).
CpG islands bound by TET2 were largely unmethylated as
measured by Infinium450k arrays (from GSE29290) and
CpG island shores showed lower methylation levels at the
TET2 bound sites relative to those not bound by TET2
(Figure 4e). We validated a number of loci identified in
the TET2 ChIP-seq by ChIP-qPCR (Additional file 13).
Interestingly, presence of TET2 associated with active
genes measured by expression arrays (GSE36133) or evi-
denced by a considerable overlap with RNA Pol2 binding
sites (ENCODE Pol2 ChIP-seq) (Figure 4f and g).
If the TETs bind to DNA and protect against hyperme-
thylation in tumours, then it would be expected that
promoters susceptible to DNA methylation gain in colon
tumours would form a distinct group with a minimal
overlap with TET target promoters. We therefore exa-
mined whether loci that gained DNA methylation in ourprimary tumours (1,597 probes for 1,077 promoters) were
likely TET2 target promoters (4,201 probes for 3,144 pro-
moters). This analysis showed less than 1% overlap bet-
ween loci that gain DNA methylation in tumours and the
TET2 bound promoters (Figure 5a). These results could
suggest that TET2 might be part of a mechanism that
protects promoters from de novo DNA methylation. To
examine this we depleted TET2 in HCT116 cells by stable
transfection of shRNAs (Figure 5b and c). In one instance
we used shRNA against TET2 alone (TET2C) and in the
other shRNA against TET2 and TET3 (TET2 + 3 where
TET3 mRNA was not affected and therefore treat this
sample as a TET2 only knockdown) (Figure 5c). LCMS
after TET2 depletion showed a marked reduction in the
global level of 5hmC (Figure 5d), confirming TET2 oxy-
genase activity in HCT116, without changes in global
levels of 5mC (Figure 5d) but this could be due to the
small contribution of promoter methylation to the methy-
lome. Infinium arrays identified several loci with changes
in DNA methylation (Figure 5e) that were for the most
part low in magnitude (median of change was 10.4%; not
shown). Similar changes in levels of DNA methylation
were recently observed after TET1 depletion in differen-
tiated cells [51]. However in our study, methylation levels
at TET2 bound CpG islands were largely unaffected after
TET2 depletion (less than 1%, Figure 5e), suggesting that
these promoters do not require high levels of TET2 to
maintain the methylation free state and are intrinsically
resistant to methylation changes.
Survival outcomes estimated from publicly available
colorectal cancer datasets [52,53] further indicate that
TET2 expression levels do not significantly associate
with patient survival, which is consistent with the small
effect that we see in these in vitro TET2 studies. TET2
therefore seems to play a moderate role in controlling
cytosine modifications during gut tumourigenesis.
Promoters with high levels of 5hmC in normal colon
overlap with bivalently marked promoters in human
embryonic stem cells that do not become methylated in
colon cancer
If tumours arise from intestinal cells in the crypt and if
5hmC is a mark of terminally differentiated cells, then
how do we explain the resistance of 5hmC promoters to
methylation gain in tumours prior to their accumulating
5hmC in normal tissue? TET2 depletion only has a
moderate effect on DNA methylation in cancer cells,
suggesting that the protective mechanism is unlikely to
be due to continuous TET2 binding at target promoters.
Although TET2 may not be involved in maintaining the
unmethylated state of its target promoters, we cannot
exclude that other proteins within a TET-complex may
be involved. However there may be alternative expla-
nations, one of which is that 5hmC promoters are
Figure 4 TET2 binds promoters of active genes in cancer cells. (a) Example of TET2 binding profile in HCT116 colorectal cancer cells. (b) TET2
binds close to TSSs and (c, d) primarily at CpG islands within HCP promoters. (e) TET2 bound islands are largely unmethylated and (f, g) associate with
active genes.
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them intrinsically unlikely to develop characteristics
such as H3K27me3 in the soma that predispose to DNA
methylation gain.
Precedents for early epigenetic marking include gen-
omic imprinting and X-inactivation, but may also in-
clude the recently described instructive process for gain
of methylation in cancer which occurs at promoters
containing histone H3K4 and H3K27 tri-methylation
(so-called bivalent promoters) in human embryonic stem
cells (hESC) [54-58]. ESCs unlike most other prolifera-
ting cells already have high levels of 5hmC. In mouse
ESCs Tet1 is found either at the TSS of bivalent pro-
moters together with silencing complexes independent
of 5hmC or downstream of the TSS together with 5hmC
and the PRC2 complex [59,60]. In human ESC 5hmC
has been found more at active gene promoters and en-
hancers than at poised (bivalent) enhancers [61].A comparison of our dataset of 5hmC marked pro-
moters to a published dataset of hESC bivalent promoters
[57] confirmed that approximately 65% of promoters that
gain methylation in our colon cancer cohort are also biva-
lently marked in hESC (Figure 6a and b). Consequently
we also examined the extent to which promoters marked
by 5hmC in normal colon overlap with bivalently marked
promoters in hESCs. We found that 30% of all 5hmC pro-
moters overlapped with bivalent genes in hESCs (Figure 6a
and b). Interestingly, these mostly coincided with bivalent
promoters that do not become hypermethylated in colo-
rectal cancer. This observation indicates that bivalent pro-
moters can be broadly separated into discrete instructive
categories: one for silencing after tissue differentiation and
susceptible to methylation gain in cancer; and another for
poised activation and acquisition of 5hmC with resistance
to methylation gain in cancer. If 5hmC is acquired as an
end point of instructive activation, this would fit with our
Figure 5 Pervasive maintenance of a methylation-free state at TET2 bound promoters. (a) DNA methylation gain in primary tumours was
remarkably scarce at the TET2 bound promoters identified in HCT116 cells (P <0.0001, binomial test). (b) Western blot for TET2 and beta TUBULIN
from whole cell extracts of HCT116 cells stably transfected with a non-targeting shRNA control (shCtrl.) or with shRNA to TET2 (TET2C) or to TET2
and TET3 (TET2 + 3). Fold change in the knockdown was calculated relative to the shCtrl. (c) qRT-PCR for TET2 and TET3. (d) Global levels of 5hmC
and 5mC by LCMS. (e) DNA methylation changes by Infinium arrays after depletion of TET2.
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ferentiated cells at genes that are active in both cancer
and normal tissue.
Conclusions
DNA methylation change is a prominent feature of cancer
and in recent years, low levels of 5hmC have been reported
as a hallmark of several cancers. We confirm that 5hmC is
strongly reduced in colon cancer cells relative to the normaltissues. However, we also find that the TETs are present in
cancer tissues, albeit at the transcript level, and with no evi-
dence for mutations that could account for the decreased
levels of 5hmC. We have recently shown that there is a
delay in the generation of 5hmC on newly synthesised
DNA [62] that can be responsible for the low levels of
5hmC in proliferating cells in the presence of TETs.
Genome-wide mapping shows that gene promoters
marked by 5hmC seem distinctly resistant to DNA
Figure 6 5hmC marked promoters are not subject to histone-bivalency-mediated methylation gain. Venn diagrams to illustrate a high
incidence of promoter methylation gain in our cohort at promoters with H3K4me3/K27me3 bivalency in human embryonic stem cells (hESCbiv).
The incidence of methylation gain is low at hESCbiv promoters marked by 5hmC in normal colon. (a) For narrow and (b) broad 5hmC promoters.
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tion loss. One explanation for this finding may be that
the TETs continue to maintain the DNA methylation
levels at promoters in the proliferating tumour cells.
However, the marginal changes in DNA methylation at a
significant number of gene promoters induced by the
TET2 knockdowns were hardly observed at promoters
we have identified as TET2 targets.
Correlative observations indicate that promoters with
5hmC in normal colon have a substantial overlap with
bivalent promoters in hESCs, and may suggest that 5hmC
is a mark of loci that have undergone a counteractive
process that prevents the acquisition of hypermethylation-
predisposing characteristics. Although we have potentially
eliminated a maintenance role for TET2 in keeping the
target promoters free of DNA methylation in colon can-
cer, this does not preclude the TETs from having an initi-
ating function that marks genes for activation during early
development. This initiating process could counter the
instructive hypermethylation in cancer process by active
removal of methylated DNA [19], by inhibiting de novo
DNA methylation [48] and/or by attracting regulatory
complexes to chromatin [63].
Finally, it has been suggested that 5hmC levels can be
used as diagnostic criteria to distinguish between benign
nevi and malignant melanomas [64]. Our study high-
lights the potential of cytosine modifications as bio-
markers of cancerous cell proliferation, but questions
whether colon cancer is suited to the recently described
potential therapeutic avenue to restore TET activity [32].
Materials and methods
Patient samples
Research was conducted under the principles of the
World Medical Association Helsinki agreement. Ethical
approval was obtained from the Cambridgeshire Local
Research Ethics Committee (LREC references 04/Q0108/
125 and 06/Q0108/307). Forty-seven normal samples
(composed of 16 samples taken more than 20 cm awayfrom tumours (normal away (NA)) and 31 samples taken
close to tumours (normal close (NC)), 36 adenoma (Ad)
and 31 adenocarcinoma (T). Samples for tissue microar-
rays are described [65].
Antibodies
Anti-5hmC rabbit polyclonal (Active Motif, 39791), anti-
TET1 (SantaCruz sc-163443), anti-TET2 for western and
IHC (Abcam ab94580), anti-TET2 for ChIP-seq (Santa
Cruz sc-136926), anti-TET3 (Abnova), anti-Lamin B1
(Abcam ab16048), anti-beta Tubulin (Sigma T0198).
hmeDIP-seq
Illumina libraries were prepared before the pull-down
using 1 to 3 micrograms of sonicated genomic DNA
(Bioruptor). Libraries were prepared using a ‘with-bead’
procedure [66] or with the TruSeq DNA sample prepa-
ration kit (Illumina) following manufacturer’s instructions.
Adaptor modified genomic DNA was then immunopreci-
pitated following [67]. Input and pull-down material was
whole genome amplified as previously described [68] ex-
cept that samples were amplified with 10 PCR cycles, ran
on 2% EX agarose gels (LifeTechnologies), size selection of
300 to 500 bp fragments with the MinElute gel extraction
kit (Qiagen), further amplified with seven PCR cycles and
purified with AMPURE XP beads. This procedure was
also done for amplification with TruSeq reagents. Libraries
were qualified and quantified by Bioanalyzer and submit-
ted for sequencing by the CI Genomics core facility.
Bioinformatic analysis - hmeDIP-seq
Illumina sequencing reads were aligned against the hg18
genome assembly using BWA. Mean read coverage
around TSS was calculated using ‘GenomicRanges’ and
‘Rsamtools’ (Bioconductor). Read coverage was norma-
lised per million mapped reads, subtracted from input
and mean TSS coverage plotted. Feature Enrichment
analysis was performed by using Rsamtools to count
reads within feature locations obtained from Ensembl
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was as described in [67]. For gene ontology, functional
enrichment of selected gene sets was assessed by fisher
exact tests with and without graph correction using the
‘TopGO’ Bioconductor package [69]. False discovery
rates were calculated by Benjamini Hochberg correction
using R [70]. For genome wide repeats analysis, repeat
scores were obtained by alignment of hmeDIP-seq reads
to a repeat genome obtained by concatenating repeat lo-
cations annotated in Ensembl. ‘DiffBind’ [71] package
was used to quantitatively compare 5hmC within peaks
in normal and tumours. Heatmaps for comparison to
meDIP-seq used ‘SeqMiner’ [72] and data kindly pro-
vided by C. Bock [43].Expression microarrays
Normal (n = 4), adenoma (n = 7) and adenocarcinoma
(tumour, n = 14) mRNA were profiled using Illumina
HumanWG6-V2 chips. The raw data were summarised
using BeadStudio version 3.1.7, without background cor-
rection and imported into R using the ‘beadarray’ package
[73] in Bioconductor. After quality control, arrays were
background corrected using a normal-exponential model
and then quantile normalised [74]. Illumina probes were
annotated using the illuminaHumanv2.db Bioconductor
package and poorly annotated probes were excluded prior
to differential expression analysis [75]. A linear modelling
approach was used to estimate the expression of each
probe in normal, adenoma, and adenocarcinoma groups.
Differential expression statistics were generated following
empirical Bayes’ shrinkage of variances [76]. Illumina ex-
pression arrays validation used the 96.96 Biomark Dynamic
Array platform (Fluidigm) and Taqman assays (ABI) fol-
lowing manufacturer’s instructions (Fluidigm). Fold change
between normal and tumour was calculated by the delta Ct
method using B2M, HPRT1, SDHA or PSMC4 as
normaliser loci (Additional file 14 and list of assays in
Additional file 1). Expression values for loci identified as
TET2 targets by ChIP-seq in HCT116 cells were ob-
tained from GSE36133.Mass spectrometry
1 μg of genomic DNA was incubated with 5 U of DNA
Degradase Plus (Zymo Research) at 37°C for 3 h and
filtered through Amicon 10 kDa centrifugal filter units
(Millipore). The concentrations of 2′-deoxycytidine, 5-
methyl-2′-deoxycytidine and 5-hydroxymethyl-2′-deoxy-
cytidine in the filtrate were determined using an AB
Sciex Triple Quad 6500 mass spectrometer fitted with
an Agilent Infinity 1290 LC system and an Acquity
UPLC HSS T3 column. The global levels of mC and
hmC were expressed as percentages over total 2′-
deoxycytidines.CRC TMA IF
After epitope retrieval by boiling in an EDTA solution the
slide was rinsed in PBS and blocked. Primary (anti-5hmC
and anti-5mC) and secondary (Alexa647 anti-rabbit and
Alexa448 anti-mouse (Invitrogen)) antibodies were se-
quentially applied for 1 h each with 3× washes of PBS/
0.1% Tween 20 in between. After a final 3× washes the
slide was mounted with DAPI and scanned onto the Ariol
system for analysis.qRT-PCR
For Figure 2, 1 μg total RNA was treated with 1U DNaseI
(Promega 9PMIM610) and cDNA prepared with Super-
scriptIII reverse transcriptase (Invitrogen) and random
primers. Targets were quantified with 1× Fast Sybr (ABI)
and 1× Quantitect assays (Qiagen) by the standard curve
method using serial dilutions of cDNA template from Jeg3
cells and normalised to B2M. For supplementary Figure 3,
1 μg RNA was reverse transcribed using Quantitect re-
verse transcription kit (Qiagen) following manufacturer’s
instructions. Real-time PCR used the 96.96 Biomark
Dynamic Array platform (Fluidigm) and Taqman assays
(ABI) following manufacturer’s instructions (Fluidigm).
Fold change between normal and tumour was calculated
by the delta Ct method using B2M as the normaliser. All
expression assays are listed in Additional file 1.Infinium27k and 450 k
Bisulfite-converted DNA (EZ DNA Methylation-Gold,
Zymo Research) was analysed using Illumina Infinium
HumanMethylation27 BeadChips in the Cambridge
Genomic Services, Cambridge University, UK. Data were
analysed using BeadStudio (Illumina, Inc.) and R. The
locus methylation was calculated as the log ratio of the
Unmethylated and Methylated channels, and a standard
error of the log-ratio was estimated. Models were fitted
with limma [77] using weights derived from the standard
errors. Separate analysis were performed for loci mea-
sured in the red channel and loci measured in the green
channel. Infinium450k for HCT116 cells in Figure 4
used beta values from GSE29290 for Infinium ID
annotations obtained using the ‘IlluminaHumanMethyla-
tion450k.db’ package (Bioconductor) in R. For the 450 k
analysis of TET2 shRNA knockdowns, raw Infinium data
were filtered by removing low quality data using a detec-
tion P value threshold of 0.05. Cross-reactive probes
(that is, targeting several genomic locations) and probes
containing SNPs were filtered out using the extended anno-
tation provided by Price et al. [78] (see [79] for a detailed
description). Probes associated to X and Y chromosomes
were removed from the analysis. Beta-values were com-
puted using the formula Beta-value =M/[U +M] where M
and U are the raw ‘methylated’ and ‘unmethylated’ signals,
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II bias using the peak-based correction [79,80].
ChIP-seq
ChIP-seq for TET2 was performed as previously de-
scribed [63].
shRNA
Stable knockdown of TET2 in HCT116 used MISSION
shRNA Lentiviral Transduction Particles (SHCLNV-NM_
017628, Sigma) following manufacturer’s instructions and
selection with 2 ug/mL Puromycin (A11138-03, Life
Technologies). For TET2C 10MOI of TRCN0000418976
and for TET2 + 3 5MOI each of TRCN0000418976
and TRCN0000246258 were used. shRNA control used
10MOI of MISSION pLKO.1-puro Non-Target shRNA
Control Transduction Particles (SHC016V-1EA, Sigma).
Additional methods
Additional methods can be found in Additional file 15.
Additional files
Additional file 1: Summarising 5hmC promoter types, loci that gain
and lose methylation in colon cancer, HCT116 TET2 target promoters,
qRT-PCR assays, Gluc-MS-qPCR primers, hmeDIP-qPCR primers, TET2
ChIP-seq qPCR validation primers, TETs targeted sequencing primers,
our colon cancer cohort and sequencing reads statistics.
Additional file 2: Figure S1. Gene ontology analysis for 5-hmC
enriched narrow and broad promoters in normal human colon. 5-hmC
profiles for the top 5 loci of each promoter type. (a) Top 20 biological
processes ranked by P value that associated with 5-hmC ‘narrow’ promoters
(top 1,000 ranked by 5-hmC content). The GO term name is followed by the
GO identifier and the term depth. Plotted alongside the P value for the term
in ‘narrow’ promoters is the value for that term in ‘broad’ promoters; this to
identify terms that are unique or shared. The dashed vertical line represents
the -log10 of P <0.05. (b) As in (a) but for ‘broad’ promoters. ‘Narrow’
promoters were enriched for membrane transport processes whereas
‘broad’ promoters were enriched for cell differentiation, developmental
processes and morphogenesis. (c) 5-hmC profiles for the top five ‘narrow’
promoters. Each frame is 6 kb (-3 kb to +3 kb of the TSS). Orange bars are
the CpG islands (UCSC). 5-hmC is highly enriched in the upstream shore of
ACTN2, CALY and ARSA promoter CpG islands, whereas 5-hmC spans across
the promoter CpG island and TSS of RTKN. RPS8 showed enrichment for
5-hmC in the gene body where the promoter for the SNORD38 gene is
present (not displayed). High content of 5-hmC is also present in the
downstream shore of CALY and ARSA promoter CpG islands. (d) 5-hmC
profiles for the top five ‘broad’ promoters where the content of 5-hmC is
similar between the upstream and downstream shores.
Additional file 3: Figure S2. Comparison of hmeDIP-seq to meDIP-seq
along with 5-hmC promoter profiles, promoter CpG content and Infinium
methylation estimates in normal colon. (a) SeqMiner [72] heatmaps of
hmeDIP-seq (this study) and meDIP-seq (from [43]) clustered by enrichment
profiles from -3 kb to +20 kb around the TSS. Ten clusters were generated.
Except for cluster 2, where a 5-mC-specific enrichment is observed at the
TSS, the enrichment profiles around genes are similar between 5-hmC and
5-mC. (b) Further comparison of 5-hmC and 5-mC profiles across all loci
from -3 kb to +3 kb around the TSS illustrates differences in enrichment
patterns at the TSS and upstream promoter region. (c) 5-hmC ‘narrow’
promoters (see main Figure 1) are typified in clusters 3 and 8 whereas
‘broad’ promoters belong to clusters 5, 6, 7 and 9. (d) Proportions of
promoters classified by their CpG content (high (HCP), intermediate(ICP), low (LCP)) in the 10 clusters. Cluster 2 is highly enriched for LCP.
(e) Comparison of DNA methylation levels by meDIP-seq from [9] to the
Infinium arrays from this study. (f) The distance of the Infinium probes
to the TSS for loci plotted in the heatmaps in (a). Collectively, these
results show that 5-hmC profiles are distinct to 5-mC profiles at a subset of
promoter regions and that the Inifinium arrays recapitulate meDIP-seq
enrichment patterns at the TSS in normal colon.
Additional file 4: Figure S3. TETs levels do not correlate with the
global change of 5-hmC in colon tumours. (a) Expression levels of
selected loci in 15 normal-tumour matched samples by Taqman qRT-PCR.
Dashed horizontal lines are at 0.6 log2 (approximately 1.5-fold linear).
(b) Correlation of changes in global 5-hmC levels (by LCMS) to the
changes in TETs expression levels in the 15 matched cases.
Additional file 5: Figure S4. TETs mutation screen. (a) Plot of sequence
coverage over amino acid residue triplets in the α-KG and Fe2 binding
sites where mutation was not detected in 36 normals, 38 adenomas,
28 adenocarcinomas or HCT116 cells. Vertical dashed line represents a
coverage of 10×. (b) Global levels of 5-hmC did not correlate with
non-synonymous mutations identified in TETs DSBH (catalytic) domain in
colon normal and cancer samples. ‘Wild-type’ (WT), heterozygous (Het),
homozygous (Hom) and not determined (ND) are indicated. Most amino
acid changes have been identified as common variants (1,000 genomes
and ESP) except TET3_R1609H and TET2_G1936D. Primer sequences are
listed in Additional file 1.
Additional file 6: Figure S5. Content of 5-hmC at repetitive elements
in normal human colon and in tumours. (a) Plotted are the percentages
of hmeDIP-seq reads in each repeat class in the bound (Bnd) and input
(Inp) fractions in normal and tumour DNA. All repeat types are enriched
for 5-hmC over input in normal tissues. Note that the ratio of Bnd to Inp
in tumours is only slightly reduced in Simple, Tandem, Dust and LTR
repeats. This ratio is clearly reduced in LINE-1, Low Complexity, SINE,
Type II transposons and the less abundant Other, Unknown and satellite
repeats. The mean and standard error of the mean are indicated.
(b, c) hmeDIP-qPCR analysis of the 5’ end of LINE-1 elements and of
alpha satellite DNA. NA is normal tissue away from the tumour, NC is
normal tissue close to the tumours, Ad is adenoma and T is adenocarcinoma.
5-hmC was enriched at the 5’ end of LINE-1 elements in NA and NC and
reduced in Ad and T. Alpha satellite showed no enrichment of 5-hmC in any
tissue but showed high levels of DNA methylation in normal tissues and
methylation loss in tumours.
Additional file 7: Figure S6. Distribution of 5-hmC in adenocarcinomas
and the correlation of reduced 5-hmC with gene activity in neoplastic
tissue. (a) Quantification of 5-hmC enrichments across genomic features.
(b) Comparison of 5-hmC distribution patterns around the TSS (-3 kb
to +20 kb of TSS) in normals and tumours. (c) Validation of the changes
in 5-hmC content in normal and tumour DNA at selected promoter and
gene body loci by Gluc-MS-qPCR. 5-hmC-specific glycosylation by the T4
glucosyltransferase inhibits MspI endonuclease activity. The plot shows
the fold change of MspI restriction activity in T4 glucosyltransferase-
treated DNA relative to non-glycosylated DNA normalised to a locus
lacking an MspI site as a loading control (vertical dashed line). 5-hmC is
clearly reduced but not absent in tumours. Primers used are listed in
Additional file 1. (d) Expression levels of genes with ‘narrow’ and ‘broad’
promoters in normals (N) and tumours (T). The marked drop in 5-hmC
does not grossly hinder the transcriptome. However a small, but
significant, decrease in activity was observed for genes with ‘broad’
5-hmC promoters (P values were calculated by a Wilcox test).
Additional file 8: Figure S7. The reciprocal pattern of 5-hmC high/low
in normal with 5-mC loss/gain in tumours is already present in adenomas
and is observed in islands, island shores and colon cancer specific DMRs.
Infinium450k annotation was used to identify CpGi relation of the
Infinium27k probes. (a) In adenomas and (b) adenocarcinomas, loci with
high content of 5-hmC in normal lose methylation in neoplastic tissues
whereas those with a low content of 5-hmC more likely gain methylation.
P values were calculated by a limma geneSetTest. (c) The reciprocal
behaviour of 5-hmC high/low with 5-mC loss/gain is observed at islands,
island shores or distant sites (shelves). Notably, 5-mC loss was more
frequent at shores but more pronounced at distant sites. On the other
hand, 5-mC gain was more frequent and more pronounced at islands.
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(d) The small differentially methylated regions (sDMR) that gain methylation
in cancer (data from [8]) are less enriched for 5-hmC in normal tissue relative
to All sDMRs whereas those that lose 5-mC in cancer have higher levels of
5-hmC in normal tissue. sDMRs cover a relatively small portion of the
genome. (e) The large blocks that lose methylation in cancer and span over
60% of the genome [8] showed depletion of 5-hmC relative to the input in
our normal tissue hmeDIP-seq. Blocks that were shown to gain methylation
in cancer and span approximately 1% of the genome di however show an
enrichment of 5-hmC reads over input in our normal tissues.
Additional file 9: Figure S8. Comparison of 5-hmC in normal human
colon to 5-mC in normal and tumour at selected WNT pathway promoters.
(a) Heatmap for a selected panel of WNT pathway components. The level of
5-hmC in normal (undetected at the 0 vertical dashed line) is compared to
the level of 5-mC in normal (0.5 vertical dashed line = 50% methylation) and
to the fold change in methylation in tumours (gain of methylation is to the
right of the 0 dashed line). Gene symbols and Infinium27k IDs are shown
on the right together with the P values for the change in methylation in
tumours. (b) Validation of the Infinium arrays by bisulphite pyrosequencing
for selected loci. The progressive gain of methylation (not shown in the
heatmap in a) from normal to adenoma to adenocarcinoma can be observed.
The low level of methylation in normal by bisulphite pyrosequencing confirms
the low level of 5-hmC in normal by hmeDIP-seq.
Additional file 10: Figure S9. Persistent presence of 5-hmC at promoters
in tumours and increased propensity to DNA methylation loss. Plot comparing
the mean methylation in normals to the methylation change in tumours
(n = 17 matched pairs). Each black dot is a single CpG and those highlighted
in grey showed a P value <0.01 for the methylation change. Red points
indicate presence of hmeDIP-seq reads above 4 in a 200 bp window around
the Infinium probe. DNA methylation was lost in 27% of gene promoters
that retain 5-hmC in tumour, whereas only 8.5% gained methylation.
Additional file 11: Figure S10. HCT116 cells have very low global
levels of 5-hmC with maintained expression of TETs. (a, b) LCMS
measurement of the global content of 5-hmC and 5-mC in our colon cancer
cohort, in HCT116 cells and mES cells genomic DNA. (c) Comparison of
TETs transcripts levels between primary tissues (N = normal, Ad = adenoma,
T = adenocarcinoma) and those in HCT116 cells. Primer sequences are listed
in Additional file 1. (d) Western blot for TETs and LaminB1 in HCT116 cells
total cell extract (T), cytoplasmic fraction (C) and nuclear fraction (N).
(e) Immunohistochemistry for TET2 in HCT116 cell pellet. Scale bar is
at 20 μm.
Additional file 12: Figure S11. TET2 protein is present in normal and
adenocarcinoma tissues. Immunohistochemistry for TET2 in normal colon
(a to d) and colon adenocarcinoma (e, f). TET2 is present mainly in the
cytoplasm of cryptal epithelium with occasional cells showing both diffuse
strong nuclear and cytoplasmic staining pattern (c, d). Predominant
cytoplasmic staining is observed in tumours (g, h). Scale bars are at 200 μm
(for a, b, e, f) or 20 μm (for c, d, g, h).
Additional file 13: Figure S12. qPCR Validation of ChIP-seq for TET2 in
HCT116 cells. ChIPs using antibodies to TET2 (sc-136926; Santa Cruz) or
IgG (sc-136926; Santa Cruz) were performed on the indicated targets
(primer sequences are available in Additional file 1). ‘% Input’ represents
real-time qPCR values normalised with respect to the input chromatin.
Values are represented as means of two independent biological
experiments. Asterisks indicate 11 out of 15 loci analysed showed
TET2-specific enrichment.
Additional file 14: Figure S13. Validation of the Illumina expression
arrays by Taqman qRT-PCR. (a) Plot comparing the fold change in
expression from normal to tumour reported by the Illumina arrays and
the fold change reported by Taqman qRT-PCR normalised to B2M. Each
value from the Illumina arrays used four normals and 14 tumours. Each
Taqman value is the average of quadruplicate measurements from 13
normal-tumour pairs. (b to d) As in (a) but normalised to HPRT1, SDHA or
PSMC4, respectively. (e) Boxplot of the fold change for the individual
assays ordered by their mean. Each assay contains 52 values from
quadruplicate measurements of 13 normal-tumour pairs. Taqman assays
are listed in Additional file 1.
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